At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Our portfolio of anti-TNF therapies is marketed in the European Union. TNF inhibitors are a type of therapy to treat inflammatory conditions such as rheumatoid arthritis (RA), psoriatic arthritis, juvenile arthritis, inflammatory bowel disease (Crohn’s and ulcerative colitis), ankylosing spondylitis, and psoriasis. They reduce inflammation and stop disease progression by targeting an inflammation-causing substance called Tumor Necrosis Factor (TNF).
These therapies are biosimilars, referencing originator products already available. By bridging our heritage of scientific innovation with an opportunity to reduce healthcare costs and increase access to biologics, developing biosimilars is a compelling way in which we can make a difference in the lives of the patients we serve.
Biogen’s science & manufacturing expertise enables production of biosimilars of advanced biologics
Biosimilars are a classification of biologic medicines that are similar to currently available biologic therapies known as originators. Having successfully delivered complex originator biologics for approximately 40 years, today Biogen is one of only a handful of companies with the leading manufacturing capabilities and the deep scientific expertise needed to produce biosimilars of advanced biologics.
As many biologics reach the end of their patent lives, Biogen believes biosimilars are central to safeguarding future healthcare innovation. Biosimilars can alleviate some of the burden on healthcare systems by offering cost savings and promoting sustainable access to therapies. Biosimilars can also expand options for patients and physicians to meet individual needs. Biogen has the expertise to manufacture and reliably supply biosimilars.
At Biogen, our goal is to provide healthcare professionals with the information needed to support their clinical practice. Three new sites have been created for healthcare professionals based in the EU. They outline important information on our products, key clinical data, supporting materials and other valuable resources.
Biogen currently serves over 200,000 patients affected by Immune Medicated Inflammatory Diseases (IMIDs) across Europe in addition to a large network of clinicians. Through our educational and digital initiatives, we aim to provide HCPs with meaningful clinical education to help them in their clinical practice. The Biosimilars Medical Academy (BMA) website has been developed with internationally renowned Key International Medical Experts (KMEs) and features key medical topics. If you are an HCP outside of the United States, please follow this link to access our website.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.